ITRM Valuation

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

ITRM Relative Valuation

ITRM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ITRM is overvalued; if below, it's undervalued.

Historical Valuation

Iterum Therapeutics PLC (ITRM) is now in the Fair zone, suggesting that its current forward PS ratio of 4.11 is considered Fairly compared with the five-year average of 392.59. The fair price of Iterum Therapeutics PLC (ITRM) is between 0.34 to 2.33 according to relative valuation methord.

Relative Value

Fair Zone

0.34-2.33

Current Price：1.10

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-8.65

P/B

Median3y

-0.93

Median5y

0.04

-69.75

FCF Yield

Median3y

-139.01

Median5y

-140.38

Competitors Valuation Multiple

The average P/S ratio for ITRM's competitors is 1.69, providing a benchmark for relative valuation. Iterum Therapeutics PLC Corp (ITRM) exhibits a P/S ratio of 4.11, which is 143.79% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

ITRM.O

Iterum Therapeutics PLC

4.11

Average P/S: 1.69

38.04M